• Corcept disclosed the DOJ declined to intervene in a civil qui tam lawsuit filed by a former employee in New Jersey federal court.
• The DOJ, California Department of Insurance, and the plaintiff states also declined to join the case, according to a May 19 notice.
• The action, filed in February 2017, targets Korlym sales and promotion, including relationships with prescribing health care professionals and reimbursement practices.
• The relator served an amended complaint on June 2; Corcept said it plans to vigorously defend against the claims.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-254622), on June 03, 2026, and is solely responsible for the information contained therein.